

IN THE CLAIMS:

Please cancel claims 86-92 and amend claims 95 and 96. This listing of the claims replaces all prior versions and listings of claims in the applications.

1-85. (Canceled)

86-92. (Canceled)

93-94. (Canceled)

95. (Currently Amended): An isolated monoclonal antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:417;
- b) a polypeptide comprising the amino acid sequence of SEQ ID NO:419;
- c) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO:415 or 416; and
- d) the polypeptide encoded by the nucleotide sequence of the DNA insert of clone EpT294, which was deposited with ATCC as Accession Number 207220.

96. (Currently Amended): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody is selected from the group consisting of:

- i) a monoclonal antibody;
- ii) a polyclonal antibody;
- [[ii]]i) a humanized antibody;
- [[iv]]ii) a chimeric antibody; and
- [[v]]iii) a human antibody.

97. (Previously Presented): The antibody, or antigen binding fragment thereof of claim 95, wherein said antigen binding fragment is a F(ab) fragment or a F(ab')₂ fragment.

98. (Previously Presented): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody binds to a polypeptide comprising amino acid residues 15-423 of SEQ ID NO:417.

99. (Previously Presented): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody binds to a polypeptide comprising amino acid residues 34 to 254 of SEQ ID NO:417.

100. (Previously Presented): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody is detectably labeled.

101. (Previously Presented): The antibody, or antigen binding fragment thereof of claim 100, wherein the detectable label is selected from the group consisting of:

- a) enzymes;
- b) prosthetic groups;
- c) fluorescent materials;
- d) luminescent materials;
- e) bioluminescent materials; and
- f) radioactive materials.

102-103. (Canceled)